(MENAFN- JCN NewsWire) Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract ...

Gene fusions are vital biomarkers for tumor diagnosis and drug development, with precise detection becoming increasingly ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug.

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

A breakthrough tool called Helicase-Assisted Continuous Editing (HACE) allows scientists to create precise genetic mutations ...

EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...

Researchers developed a barcoded directed evolution system for engineered virus-like particles (eVLPs), creating a ...

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.